Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Single Agent Tazemetostat in Subjects With Advanced Solid Tumors and B-Cell Lymphomas With Hepatic Dysfunction

NCT03217253 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03217253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03217253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Single Agent Tazemetostat in Subjects With Advanced Solid Tumors and B-Cell Lymphomas With Hepatic Dysfunction
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Withdrawn
Start date
March 16, 2018
Completion date
September 19, 2019
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage iii b-cell non-hodgkin lymphoma, ann arbor stage iv b-cell non-hodgkin lymphoma, metastatic malignant solid neoplasm, stage iii hepatocellular carcinoma ajcc v7, stage iiia hepatocellular carcinoma ajcc v7, stage iiib hepatocellular carcinoma ajcc v7, stage iiic hepatocellular carcinoma ajcc v7, stage iv hepatocellular carcinoma ajcc v7, stage iva hepatocellular carcinoma ajcc v7, stage ivb hepatocellular carcinoma ajcc v7, unresectable solid neoplasm